Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Beloranib

Stage Phase 3Stale

Sponsor Zafgen, Inc.

Route injection

Class MetAP2 inhibitor

Mechanism methionine aminopeptidase 2 inhibitor

Sources

registry, as of 2011-12-30Stale

https://clinicaltrials.gov/study/NCT01028261

Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers. Overall status COMPLETED. Phases PHASE1. Lead sponsor Zafgen, Inc.. Enrollment 31. Conditions Obesity. The purpose of this study is to assess whether multiple doses of ZGN-433 is safe and well tolerated in obese female subjects. The study will also provide information on how much ZGN-433 gets into the blood, how long does it stay in the body, and how it affects other biological ma

ClinicalTrials.gov NCT01028261 protocol and results modules

registry, as of 2016-07-14Stale

https://clinicaltrials.gov/study/NCT01666691

An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor Zafgen, Inc.. Enrollment 160. Conditions Obesity. The purpose of this study is to evaluate weight reduction, safety and pharmacokinetics for certain doses of beloranib (ZGN-440 for injectable suspension) administered as twice-weekly subcutaneous injections for 12 weeks.

ClinicalTrials.gov NCT01666691 protocol and results modules

registry, as of 2016-07-18Stale

https://clinicaltrials.gov/study/NCT02063295

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury. Overall status COMPLETED. Phases PHASE2. Lead sponsor Zafgen, Inc.. Enrollment 14. Conditions Obesity; Over-weight; Hypothalamic Injury; Craniopharyngioma. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of beloranib in obese subjects with hypothalamic injury.

ClinicalTrials.gov NCT02063295 protocol and results modules

registry, as of 2017-01-26Stale

https://clinicaltrials.gov/study/NCT02179151

Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome. Overall status TERMINATED. Phases PHASE3. Lead sponsor Zafgen, Inc.. Enrollment 108. Conditions Prader-Willi Syndrome; Obesity. The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adolescent and adult subjects with Prader-Willi Syndrome.

ClinicalTrials.gov NCT02179151 protocol and results modules

registry, as of 2016-07-18Stale

https://clinicaltrials.gov/study/NCT01818921

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome. Overall status COMPLETED. Phases PHASE2. Lead sponsor Zafgen, Inc.. Enrollment 17. Conditions Obesity; Over-weight; Prader-Willi Syndrome. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics for certain doses of beloranib in obese subjects with Prader-Willi Syndrome.

ClinicalTrials.gov NCT01818921 protocol and results modules

registry, as of 2011-12-30Stale

https://clinicaltrials.gov/study/NCT01372761

Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers. Overall status COMPLETED. Phases PHASE1. Lead sponsor Zafgen, Inc.. Enrollment 25. Conditions Obesity. The purpose of this study is to assess whether multiple doses of ZGN-433 are safe and effective.

ClinicalTrials.gov NCT01372761 protocol and results modules

publication, as of 2018-07-20Stale

https://pubmed.ncbi.nlm.nih.gov/28556449/

The bestPWS clinical trial assessed the efficacy, safety and tolerability of the methionine aminopeptidase 2 (MetAP2) inhibitor, beloranib. Participants with PWS (12-65 years old) were randomly assigned (1:1:1) to biweekly placebo, 1.8 mg beloranib or 2.4 mg beloranib injection for 26 weeks at 15 US sites. Co-primary

PMID 28556449

Studies

Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers

Registry NCT01028261

Phase Phase 1

Status Completed

Enrollment 31

ZGN-433

Regimen weekly

Weeks 6

Comparator placebo

Population Obesity

Normal Saline

Regimen weekly

Weeks 6

Population Obesity

An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects

Registry NCT01666691

Phase Phase 2

Status Completed

Enrollment 160

Placebo

Regimen weekly

Weeks 12

Population Obesity

0.3 mg Beloranib

Dose 0.3 mg

Regimen weekly

Weeks 12

Comparator placebo

Population Obesity

0.6 mg Beloranib

Dose 0.6 mg

Regimen weekly

Weeks 12

Comparator placebo

Population Obesity

1.2 mg Beloranib

Dose 1.2 mg

Regimen weekly

Weeks 12

Comparator placebo

Population Obesity

2.4 mg Beloranib

Dose 2.4 mg

Regimen weekly

Weeks 12

Comparator placebo

Population Obesity

3.2 mg Beloranib

Dose 3.2 mg

Regimen weekly

Weeks 12

Comparator placebo

Population Obesity

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

Registry NCT02063295

Phase Phase 2

Status Completed

Enrollment 14

ZGN-440 sterile diluent

Regimen weekly

Weeks 4

Population Obesity; Over-weight; Hypothalamic Injury; Craniopharyngioma

ZGN-440 for injectable suspension

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity; Over-weight; Hypothalamic Injury; Craniopharyngioma

bestPWS

Registry NCT02179151

Phase Phase 3

Status Terminated

Enrollment 108

Placebo

Regimen weekly

Weeks 28

Population Prader-Willi Syndrome; Obesity

ZGN-440 Injectable Suspension (1.8 mg)

Dose 1.8 mg

Regimen weekly

Weeks 28

Comparator placebo

Population Prader-Willi Syndrome; Obesity

ZGN-440 Injectable Suspension (2.4 mg)

Dose 2.4 mg

Regimen weekly

Weeks 28

Comparator placebo

Population Prader-Willi Syndrome; Obesity

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

Registry NCT01818921

Phase Phase 2

Status Completed

Enrollment 17

ZGN-440 sterile diluent

Regimen weekly

Weeks 4

Population Obesity; Over-weight; Prader-Willi Syndrome

1.2 mg ZGN-440 for injectable suspension

Dose 1.2 mg

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity; Over-weight; Prader-Willi Syndrome

1.8 mg ZGN-440 for injectable suspension

Dose 1.8 mg

Regimen weekly

Weeks 4

Comparator placebo

Population Obesity; Over-weight; Prader-Willi Syndrome

Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers

Registry NCT01372761

Phase Phase 1

Status Completed

Enrollment 25

Normal Saline

Regimen weekly

Population Obesity

ZGN-433

Regimen weekly

Comparator placebo

Population Obesity